| Drug General Information |
| Drug ID |
D07JKY
|
| Former ID |
DIB009207
|
| Drug Name |
KP-496
|
| Indication |
Asthma [ICD10:J45]
|
Phase 2 |
[1]
|
|---|
| CAS Number |
CAS 192814-01-0
|
| Target and Pathway |
| Target(s) |
Cysteinyl leukotriene receptor 1 |
Target Info |
Modulator |
[1]
|
|---|
| Thromboxane A2 receptor |
Target Info |
Modulator |
[1]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Platelet activation
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
Pathway Interaction Database
|
Endothelins
|
|
Reactome
|
Leukotriene receptors
|
|
G alpha (q) signalling eventsR-HSA-391908:Prostanoid ligand receptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling events
|
|
Thromboxane signalling through TP receptor
|
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
|
Small Ligand GPCRs
|
|
Signal amplification
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10. |
|---|
